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Abstract
Background: Phosphatidylserine (PS) is a naturally occurring phospholipid present in the inner leaflet of
mammalian plasma membranes. Administration of PS extracted from bovine cortex (BC-PS), which contains high
levels of omega-3 long chain polyunsaturated fatty acid (LC-PUFA) attached to its backbone, resulted in positive
effects on brain functions such as learning and memory. Recently, a novel marine-sourced PS with omega-3 LC-
PUFA attached to its backbone was developed (PS-DHA). In the present study, we evaluated the safety profile of
the novel PS preparation in non-demented elderly with memory complaints. The efficacy study of this novel
formulation indicated that PS-DHA may ameliorate cognitive deficits in non-demented elderly population.
Methods: 157 non-demented elderly participants with memory complaints were randomized to receive either PS-DHA
(300 mg PS/day) or placebo for 15 weeks. Standard biochemical and hematological safety parameters, blood pressure
and heart rate were evaluated at baseline and endpoint. 122 participants continued into an open-label extension for
additional 15 weeks, in which they all consumed PS-DHA (100 mg PS/day) and were evaluated for their blood pressure,
heart rate and weight at endpoint. Adverse events were monitored throughout the double-blind and open-label phases.
Results: 131 participants completed the double-blind phase. No significant differences were found in any of the
tested safety parameters between the study groups, or within each group. 121 participants completed the open-
label phase. At the end of this phase, there was a reduction in resting diastolic blood pressure and a slight weight
gain among participants who consumed PS-DHA for 30 weeks.
Conclusions: The results of this study indicate that consumption of PS-DHA at a dosage of 300 mg PS/day for 15
weeks, or 100 mg PS/day for 30 weeks, is safe, well tolerated, and does not produce any negative effects in the
tested parameters.
Trial registration: clinicaltrials. gov, identifier: NCT00437983
Background
Phosphatidylserine (PS) is a naturally occurring phos-
pholipid present in the inner leaflet of mammalian
plasma membranes. In humans, PS is most concentrated
in the brain where it comprises 15% of the total phos-
pholipid pool. PS has been shown to play a key role in
the functioning of neuron membranes, such as signal
transduction, secretory vesicle release and cell-to-cell
communication [1].
The administration of PS extracted from bovine cortex
(BC-PS) has positive effects on brain function. BC-PS was
shown to improve learning and memory in age-associated
memory impaired subjects [2], to enhance behavioral and
cognitive parameters in geriatric patients [3], and to
improve cognitive performance of Alzheimer’s disease
(AD) patients [4,5]. Although the primary objective of
clinical studies involving BC-PS was to test efficacy, no
significant adverse events were reported following oral
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up to 3 months [2-8]. In the largest double-blind, pla-
cebo-controlled trial [3], comprising 494 participants, only
one subject dropped out because of an adverse event, as
compared to seven drop-outs from the placebo group.
Due to safety concerns about potential contamination
by bovine spongiform encephalopathy (BSE) prions in
recent years, alternatives to BC-PS, such as soy derived
PS (SB-PS), have been developed. SB-PS however, differs
considerably in its fatty acid composition as compared
to mammalian brain PS, and while SB-PS was shown to
attenuate both physical [9] and mental stress [10,11],
further research is required to determine its ability to
promote cognitive functioning [12,13]. The safety of SB-
PS was tested in a double-blind placebo controlled study
on 120 elderly [14]. Hematological and biochemical
parameters along with vital signs and adverse events
were evaluated after 6 and 12 weeks of treatment. The
study conclusion was that SB-PS is safe for administra-
tion to older persons if taken up to a dosage of 600 mg/
day [14].
To gain the benefits of mammalian PS without the
attendant risks, a safe, marine-sourced PS with omega-3
long chain polyunsaturated fatty acid (LC-PUFA) attached
to its backbone was developed. This compound was
recently found to improve the symptoms of children with
impaired visual sustained attention [15] and to protect
middle-aged rats from scopolamine-induced deleterious
effects [16]. However, the biochemical and hematological
tolerability of PS with omega-3 attached to its backbone
have not been presented until now.
In the present report we describe the safety of a novel
formulation of PS with omega-3 LC-PUFA, mainly doco-
sahexaenoic acid (DHA), attached to its glycerol back-
bone (PS-DHA), in non-demented elderly. The relevant
safety parameters were derived from biochemical and
hematological variables, examination of vital signs and
adverse events monitoring during the 15 weeks double-
blind placebo controlled study and from examination of
vital signs and adverse events monitoring during the 15
additional weeks of the open-label extension phase. The
efficacy of this novel formulation has also been tested in
this population and the results of the double-blind phase
are reported elsewhere [17]. Briefly, the study results
indicated that PS-DHA may improve cognitive perfor-
mance in non-demented elderly with memory complaints
as PS-DHA administration resulted in an improvement
of verbal immediate memory and in higher responders
rates in comparison with the placebo group [17].
Methods
Subjects
Participants were recruited through advertisements in
senior citizens homes, hospitals, and newspapers.
Approximately 700 elderly were screened for enrollment
to the study. Out of them 157 non-demented participants
with memory complaints met t h ep r e v i o u s l yd e s c r i b e d
inclusion criteria [17]. Briefly, eligible participants were
non-demented men or women between the ages of 50
and 90 years, with complaints of memory loss [18] and
no evidence of a condition that could produce cognitive
deterioration including AD, Parkinson’s disease, stroke,
normal pressure hydrocephalus, and other brain lesions
including tumors, renal, respiratory, cardiac, and hepatic
disease, diabetes mellitus, endocrine, metabolic or hema-
tological disturbances unless well controlled, and malig-
nancy not in remission for more than two years.
Concomitant use of drugs or supplements affecting cog-
nitive function was prohibited.
The study was conducted according to the principles of
the Declaration of Helsinki and good clinical practice.
The protocol was approved by the Ethics Committee of
the Sourasky Medical Center, Tel-Aviv, Israel, and all
volunteers gave written informed consent prior to
participation.
Study Design
The study was designed as a single-center, randomized,
double-blind, placebo-controlled, 15 weeks study, followed
by an open-label extension of additional 15 weeks. At the
first, double–blind, phase, participants were randomized
according to a computerized process based on 6 and 8
blocks, in a 1:1 ratio stratified by gender, to receive three
capsules per day of PS-DHA or a matched identically
looking placebo (cellulose). The daily PS-DHA dosage pro-
vided 300 mg PS and 79 mg DHA+EPA (DHA:EPA ratio
of 3:1). During the second, open-label, phase, participants
consumed one capsule a day of PS-DHA. The daily dosage
provided 100 mg PS and 26 mg DHA+EPA. PS-DHA
(Vayacog™) was supplied by Enzymotec, Migdal HaEmeq,
Israel.
Safety was evaluated by clinical laboratory assessments
including biochemical and hematological parameters at
baseline and endpoint of the double-blind phase and by
adverse events recording, physical examination and mea-
surement of vital signs and weight at baseline, week 7 and
endpoint (week 15) of the double-blind phase and at the
end of the open-label extension (week 30).
Blood samples were analyzed by the American Medi-
cal Laboratories (AML), Herzliya, Israel. Adverse events
were monitored and recorded at each visit and by tele-
phone contact every other week.
Laboratory Parameters
Biochemical parameters consisted of potassium, sodium,
calcium, phosphorus, chloride, glucose, creatinine, blood
urea nitrogen (BUN), bilirubin, total protein and lipid
profile (total cholesterol, triglycerides, HDL, and LDL),
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ase (AST), and alkaline phosphatase. Hematology con-
sisted of red blood cell count, hematocrit, hemoglobin,
white blood cell count and differential, platelets, MCV,
MCH, and MCHC.
Physical parameters
The parameters assessed were weight, resting systolic
and diastolic blood pressure, and pulse rate.
Statistical Analysis
Two-sided Student’st - t e s tf o rd e p e n d e n ts a m p l e sw a s
used to analyze changes between different points in time
in the tested parameters, in the whole group and in each
gender separately, for both arms.
Two-sided t-test for independent samples was used to
analyze differences between arms in the change between
baseline and week 15 in blood parameters, vital signs and
weight, in the whole group and in each gender separately
and to detect any difference between groups in the fre-
quency of adverse events.
Pearson’s chi-square test for categorical variables was
used to analyze the differences between groups in the
number of participants who reported adverse events.
In the analysis of differences between and within
groups, P values were adjusted for the number of para-
meters analyzed using Bonferroni correction. SAS statis-
tical package (version 9.1) was used for all analyses.
Results
Study Population
A total of 157 participants underwent randomization (79
were assigned to PS-DHA treatment and 78 to placebo
treatment). One hundred and thirty one participants
completed the double-blind study (66 in the treatment
group and 65 in the placebo group). Drop-outs were
distributed equally over the two arms and reasons for
discontinuation were generally similar across the treat-
ment groups (Table 1). Average age of participants who
completed the double-blind study (± SD) was 72.42 ±
8.02 in the PS-DHA group and 72.73 ± 8.25 in the pla-
cebo group. There were no significant differences
between treatment groups in the incidence of existing
disorders including cardiovascular disease and endocrine
or metabolic disorders.
Sixty one participants from the PS-DHA group (PS-
DHA continuers) and 61 from the placebo group (PS-
naive) continued into the open-label 15 weeks extension
period. One participant from the PS-DHA naive group
dropped out from the study due to protocol violation.
Average age of participants who completed the open-
label extension (± SD) was 72.36 ± 7.93 in the PS-DHA
continuers group and 72.73 ± 8.31 in the PS-DHA naive
group.
Safety parameters
Physical parameters values during the double-blind phase
are presented in Table 2. No significant changes from
baseline in resting systolic and diastolic pressure, resting
pulse rate and weight were found between treatment
groups. A statistically significant increase in weight (0.45 ±
0.04 kg) was detected in the PS-DHA group during the
course of the double-blind phase. However, this elevation
did not survive Bonferroni correction. Physical parameter
values of PS-DHA continuers, who completed the open-
label phase, are presented in Table 3. A statistically signifi-
cant decrease in resting diastolic BP (3.1 ± 0.3 mmHg)
and a slight increase in weight (0.61 ± 0.05 kg) were
observed following 30 weeks of PS-DHA administration.
Among PS-DHA naive participants, who received PS-
DHA for 15 weeks, there were no significant changes in
any of the tested physical parameters at the end of the
open-label phase (data not shown).
Biochemical parameters values during the double-blind
phase are presented in Table 4. No significant differences
between groups were observed in the biochemical para-
meters, except for minor differences in sodium, calcium,
chloride and females triglyceride levels. However, these
differences did not survive Bonferroni correction and
hence were rendered insignificant. In addition, during the
course of the double-blind phase there were few para-
meters that showed a statistically significant change from
baseline in the PS-DHA group, and other parameters in
the placebo group. However again, the correction ren-
dered them insignificant.
Hematological parameters values during the double-
blind phase are presented in Table 5. No significant dif-
ferences between groups were observed, except for a
minor difference in the neutrophils count of the female
population. Again, this difference did not survive Bon-
ferroni correction and hence was rendered insignificant.
In addition, during the course of the double-blind phase
there were few hematological parameters that showed
slight changes from baseline in the PS-DHA group, and
other parameters in the placebo group, however again,
the correction rendered them insignificant.
Table 1 Reasons for study discontinuation
Reason PS-DHA Placebo
Protocol violation 2 1
Withdrawn consent 5 6
Adverse events* 5 5
Severe adverse events** 1
# 1
##
Sum 13 13
* Adverse events are specified in Table 6
** Classified by the study physician as not related to the study treatment
# Hospitalization due to hyponatremia
## Hospitalization due to atrial fibrillation and epigastric pain
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Adverse events reported during the course of the dou-
ble-blind phase are presented in Table 6. Twenty parti-
cipants from the PS-DHA and 11 participants from the
placebo group reported adverse events (29 and 15
adverse events, respectively). There were no significant
differences between the study groups in the number of
participants who reported an adverse event (P = 0.078)
or in the number of reported adverse events (P = 0.087).
Ten participants from the PS-DHA group and 8 partici-
pants from the placebo group were classified by the
study physicians as suffering from related or probably
related adverse events (16 and 11 adverse events, respec-
tively). Again, there were no significant differences
between the study groups in the number of participants
who reported an adverse event (P = 0.637) or in the
number of reported adverse events, classified as related
or probably related to the study treatment (P = 0.472).
During the course of the double-blind phase, there
were 5 severe adverse events (suspected acute diverticuli-
tis, benign prostatic hyperplasia surgery, and 3 hospitali-
zations due to hyponatremia, bradycardia and abdominal
Table 2 Physical parameters values at baseline and following 15 weeks of double-blind treatment
PS-DHA Placebo
Variable Baseline
(mean ± SD)
15 weeks
(mean ± SD)
P value
1 (within
group)
Baseline
(mean ± SD)
15 weeks
(mean ± SD)
P value
1 (within
group)
P value
2 (between
groups)
Resting systolic
BP (mm Hg)
127.1 ± 13.4 128.4 ± 15.4 0.511 127.6 ± 15.8 127.8 ± 16.5 0.909 0.685
Male 125.4 ± 13.5 126.8 ± 14.6 0.612 129.0 ± 13.0 131.7 ± 12.6 0.244 0.691
Female 128.8 ± 13.3 130.0 ± 16.2 0.676 126.1 ± 18.7 123.3 ± 19.5 0.330 0.331
Resting diastolic
BP (mm Hg)
73.8 ± 9.2 72.6 ± 9.1 0.299 75.0 ± 7.9 73.3 ± 9.4 0.159 0.746
Male 73.9 ± 9.3 71.7 ± 9.0 0.188 75.4 ± 8.0 73.9 ± 9.7 0.289 0.795
Female 73.6 ± 9.2 73.4 ± 9.3 0.893 74.6 ± 7.8 72.7 ± 9.2 0.357 0.516
Resting pulse
(beats/minute)
69.4 ± 10.1 69.9 ± 9.5 0.657 66.5 ± 8.4 67.6 ± 10.1 0.394 0.725
Male 69.1 ± 11.8 69.8 ± 10.8 0.648 63.9 ± 7.8 66.1 ± 10.1 0.139 0.482
Female 69.7 ± 8.4 69.9 ± 8.2 0.872 69.6 ± 8.2 69.3 ± 9.6 0.865 0.812
Weight (kg) 70.3 ± 11.2 70.8 ± 11.6 0.033* 73.0 ± 12.9 73.3 ± 13.3 0.209 0.622
Male 77.4 ± 9.6 78.0 ± 9.9 0.036* 79.1 ± 11.1 79.5 ± 11.5 0.235 0.664
Female 63.7 ± 8.3 64.0 ± 8.7 0.359 66.1 ± 11.4 66.3 ± 11.9 0.640 0.746
1 Based on two-sided t test for dependent samples.
2 Based on two-sided t test for independent samples.
* Statistical significance was not maintained following Bonferonni correction.
In the treatment arm, 32 males and 33 females had blood pressure and pulse measurements at baseline and endpoint and 31 males and 33 females had weight
measurements at baseline and endpoint. In the placebo arm, 34 males and 29 females had blood pressure and pulse measurements at baseline and endpoint
and 33 males and 29 females had weight measurements at baseline and endpoint.
Table 3 Physical parameters values of PS-DHA continuers* at baseline and following 30 weeks of treatment
Variable Baseline (mean ± SD) 30 weeks (mean ± SD) P value
Resting systolic BP (mm Hg) 127.2 ± 13.5 126.3 ± 14.0 0.594
Male 125.7 ± 13.7 126.5 ± 14.3 0.716
Female 128.6 ± 13.4 126.0 ± 14.0 0.366
Resting diastolic BP (mm Hg) 73.8 ± 9.4 70.7 ± 9.8 0.006
Male 73.8 ± 9.7 71.6 ± 8.7 0.195
Female 73.8 ± 9.3 69.9 ± 10.7 0.010
Resting pulse (beats/minute) 69.4 ± 10.0 70.6 ± 11.9 0.368
Male 69.3 ± 11.6 71.1 ± 13.4 0.412
Female 69.5 ± 8.5 70.1 ± 10.6 0.687
Weight (kg) 70.0 ± 11.2 70.7 ± 11.4 0.015
Male 77.1 ± 9.6 77.7 ± 9.8 0.067
Female 63.7 ± 8.5 64.3 ± 8.8 0.104
* include 29 males and 32 females.
P value based on two-sided t test for dependent samples.
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PS-DHA Placebo
Variable Baseline
(mean ± SD)
15 weeks
(mean ± SD)
P value
1 (within
group)
Baseline
(mean ± SD)
15 weeks
(mean ± SD)
P value
1 (within
group)
P value
2 (between
groups)
Glucose (mg/dL) 106.6 ± 34.0 105.9 ± 37.1 0.885 103.4 ± 30.7 111.1 ± 47.3 0.082 0.175
Male 115.1 ± 42.0 110.4 ± 47.4 0.551 105.8 ± 33.6 118.3 ± 59.9 0.076 0.101
Female 98.0 ± 20.7 101.5 ± 22.5 0.330 100.6 ± 27.3 102.9 ± 25.6 0.662 0.847
Sodium (mmol/L) 140.6 ± 2.6 140.9 ± 2.7 0.316 140.9 ± 2.1 140.3 ± 2.3 0.014* 0.017*
Male 140.6 ± 2.6 140.9 ± 2.7 0.352 141.2 ± 2.0 140.6 ± 2.1 0.092 0.061
Female 140.5 ± 2.7 140.8 ± 2.7 0.582 140.6 ± 2.2 140.0 ± 2.5 0.079 0.136
Calcium (mg/dL) 9.6 ± 0.6 9.6 ± 0.5 0.452 9.4 ± 0.6 9.6 ± 0.5 0.012* 0.038*
Male 9.5 ± 0.4 9.5 ± 0.5 0.966 9.4 ± 0.3 9.5 ± 0.4 0.189 0.413
Female 9.8 ± 0.7 9.6 ± 0.5 0.371 9.5 ± 0.8 9.7 ± 0.5 0.032* 0.051
Phosphorus (mg/
dL)
3.4 ± 0.6 3.3 ± 0.5 0.103 3.4 ± 0.5 3.3 ± 0.5 0.346 0.807
Male 3.2 ± 0.6 3.1 ± 0.5 0.190 3.2 ± 0.5 3.2 ± 0.5 0.636 0.671
Female 3.7 ± 0.5 3.6 ± 0.5 0.326 3.5 ± 0.6 3.4 ± 0.5 0.397 0.932
Chloride (mmol/L) 101.6 ± 3.1 102.4 ± 3.0 0.010* 101.9 ± 3.1 101.8 ± 2.3 0.880 0.047*
Male 101.9 ± 2.8 102.6 ± 3.0 0.094 102.1 ± 3.0 102.1 ± 2.2 1.000 0.262
Female 101.2 ± 3.4 102.2 ± 2.9 0.053 101.6 ± 3.4 101.5 ± 2.4 0.819 0.104
Potassium (mmol/L) 4.6 ± 0.5 4.5 ± 0.3 0.031* 4.6 ± 0.5 4.7 ± 0.7 0.703 0.128
Male 4.8 ± 0.7 4.6 ± 0.4 0.095 4.7 ± 0.4 4.7 ± 0.6 0.977 0.221
Female 4.5 ± 0.3 4.4 ± 0.3 0.173 4.6 ± 0.6 4.6 ± 0.8 0.638 0.345
BUN (mg/dL) 18.5 ± 4.9 18.9 ± 4.8 0.321 18.6 ± 5.2 19.7 ± 6.7 0.039* 0.262
Male 19.6 ± 4.8 19.9 ± 4.9 0.679 20.5 ± 5.3 21.7 ± 7.2 0.101 0.249
Female** 17.4 ± 4.9 18.0 ± 4.7 0.345 16.3 ± 4.1 17.3 ± 5.3 0.225 0.680
Creatinine (mg/dL) 0.9 ± 0.2 0.9 ± 0.2 0.223 0.9 ± 0.2 0.9 ± 0.2 0.416 0.953
Male 1.0 ± 0.2 1.0 ± 0.2 0.507 1.0 ± 0.3 1.0 ± 0.3 0.617 0.420
Female 0.8 ± 0.1 0.8 ± 0.2 0.237 0.7 ± 0.2 0.8 ± 0.2 0.041* 0.265
Alkaline
Phosphatase (U/L)
68.3 ± 22.5 67.3 ± 22.6 0.331 69.9 ± 30.0 69.4 ± 27.8 0.578 0.726
Male 69.6 ± 24.9 68.0 ± 25.7 0.380 73.3 ± 36.2 72.1 ± 33.0 0.286 0.842
Female 67.1 ± 20.1 66.7 ± 19.4 0.693 66.0 ± 20.8 66.3 ± 20.3 0.862 0.724
ALT/SGPT (U/L) 23.9 ± 26.4 20.7 ± 8.4 0.282 19.3 ± 6.4 19.5 ± 5.8 0.733 0.262
Male 28.9 ± 36.3 22.3 ± 9.7 0.273 19.2 ± 5.9 19.2 ± 5.8 1.000 0.276
Female 18.9 ± 6.8 19.0 ± 6.6 0.869 19.5 ± 7.1 19.9 ± 5.8 0.655 0.794
AST/SGOT (U/L) 25.2 ± 20.8 22.4 ± 6.1 0.250 21.9 ± 6.2 21.8 ± 5.3 0.879 0.280
Male 28.6 ± 28.6 23.3 ± 7.1 0.276 21.8 ± 5.7 21.3 ± 5.5 0.536 0.329
Female 21.9 ± 6.5 21.5 ± 5.0 0.685 21.9 ± 6.8 22.3 ± 5.0 0.704 0.577
Total Bilirubin (mg/
dL)
0.6 ± 0.2 0.6 ± 0.3 0.361 0.6 ± 0.3 0.6 ± 0.3 0.673 0.747
Male 0.6 ± 0.3 0.6 ± 0.3 0.097 0.7 ± 0.3 0.7 ± 0.3 0.325 0.753
Female 0.5 ± 0.2 0.5 ± 0.2 0.699 0.5 ± 0.2 0.5 ± 0.2 0.423 0.826
Total Protein (g/dL) 7.3 ± 0.4 7.3 ± 0.4 0.190 7.3 ± 0.5 7.4 ± 0.5 0.188 0.936
Male 7.3 ± 0.4 7.3 ± 0.5 0.358 7.3 ± 0.4 7.3 ± 0.5 0.990 0.489
Female 7.3 ± 0.4 7.3 ± 0.4 0.362 7.4 ± 0.6 7.5 ± 0.4 0.091 0.443
Triglycerides (mg/
dL)
141.6 ± 61.4 133.0 ± 70.0 0.133 128.9 ± 54.8 131.6 ± 58.5 0.677 0.186
Male 138.2 ± 68.1 133.8 ± 79.6 0.577 131.6 ± 54.9 121.7 ± 42.2 0.198 0.611
Female 145.1 ± 54.8 132.2 ± 60.0 0.132 125.9 ± 55.4 142.8 ± 71.9 0.103 0.025*
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HDL (mg/dL) 54.8 ± 12.4 56.4 ± 13.4 0.118 53.7 ± 14.1 54.4 ± 14.1 0.430 0.505
Male 48.8 ± 9.6 50.4 ± 10.5 0.044* 48.3 ± 10.2 49.2 ± 11.2 0.348 0.604
Female 60.9 ± 12.1 62.4 ± 13.4 0.404 59.9 ± 15.4 60.3 ± 14.9 0.785 0.635
LDL (mg/dL) 97.6 ± 31.4 98.6 ± 31.7 0.745 98.9 ± 30.9 99.1 ± 25.6 0.940 0.853
Male 88.6 ± 30.4 91.0 ± 31.8 0.287 94.4 ± 28.9 92.9 ± 21.2 0.656 0.332
Female 106.6 ± 30.2 106.2 ± 30.2 0.946 104.1 ± 32.8 106.2 ± 28.5 0.672 0.743
Total cholesterol
(mg/dL)
177.5 ± 38.2 181.1 ± 35.2 0.402 178.0 ± 37.2 179.4 ± 33.7 0.650 0.687
Male 164.6 ± 31.2 167.6 ± 33.1 0.283 168.5 ± 33.2 166.0 ± 26.3 0.487 0.226
Female 190.3 ± 40.6 194.5 ± 32.4 0.613 188.7 ± 39.0 194.6 ± 35.1 0.284 0.856
1 Based on two-sided t test for dependent samples.
2 Based on two-sided t test for independent samples
* Statistical significance was not maintained following Bonferonni correction
In the treatment arm, 33 males and 33 females had biochemical blood measurements at baseline and endpoint.
In the placebo arm, 34 males and 30 females had biochemical blood measurements at baseline and endpoint.
** In the placebo arm 29 females had BUN measurements at baseline and endpoint.
Table 5 Hematological parameters values at baseline and following 15 weeks of double-blind treatment
PS-DHA Placebo
Variable Baseline (mean
± SD)
15 weeks
(mean ±
SD)
P value
1 (within
group)
Baseline (mean
± SD)
15 weeks
(mean ±
SD)
P value
1 (within
group)
P value
2 (between
groups)
White blood cell count
(×10
3/cmm)
6.8 ± 1.8 6.5 ± 1.6 0.083 7.1 ± 2.0 6.7 ± 1.9 0.011* 0.434
Male 6.8 ± 1.7 6.4 ± 1.5 0.020* 7.3 ± 2.3 7.1 ± 2.2 0.298 0.467
Female 6.7 ± 1.9 6.7 ± 1.6 0.829 6.9 ± 1.4 6.3 ± 1.3 0.009* 0.066
Red blood cell count (×10
6/
cmm)
4.6 ± 0.5 4.6 ± 0.5 0.441 4.6 ± 0.4 4.6 ± 0.4 0.332 0.765
Male 4.7 ± 0.5 4.7 ± 0.5 0.544 4.6 ± 0.4 4.6 ± 0.4 0.491 0.925
Female 4.5 ± 0.4 4.4 ± 0.4 0.622 4.5 ± 0.4 4.5 ± 0.4 0.488 0.760
Hematocrit (%) 41.2 ± 4.2 40.7 ±
4.3
0.113 41.6 ± 3.6 40.9 ±
3.6
0.045* 0.504
Male 42.5 ± 4.3 42.1 ±
4.4
0.229 42.6 ± 3.6 42.0 ±
3.4
0.100 0.763
Female 39.8 ± 3.7 39.4 ±
3.8
0.309 40.5 ± 3.2 39.6 ±
3.5
0.193 0.548
Hemoglobin (g/dL) 13.7 ± 1.5 13.7 ±
1.5
0.434 13.7 ± 1.2 13.6 ±
1.2
0.213 0.669
Male 14.3 ± 1.4 14.3 ±
1.3
0.706 14.1 ± 1.2 13.9 ±
1.2
0.181 0.623
Female 13.1 ± 1.4 13.0 ±
1.4
0.481 13.3 ± 1.1 13.2 ±
1.1
0.494 0.856
Platelet count (×10
3/cmm) 221.5 ± 62.7 226.8 ±
60.5
0.374 226.9 ± 73.7 230.8 ±
68.8
0.347 0.839
Male 200.1 ± 44.5 204.0 ±
44.3
0.479 202.8 ± 58.3 210.0 ±
61.1
0.128 0.648
Female 243.5 ± 71.3 250.2 ±
66.4
0.536 255.4 ± 80.6 255.3 ±
70.4
0.980 0.592
Netrophils (%) 62.8 ± 6.5 62.4 ±
6.4
0.514 63.8 ± 8.7 62.9 ±
8.6
0.207 0.543
Male 65.1 ± 6.0 64.4 ±
5.7
0.390 64.8 ± 9.0 64.8 ±
9.2
0.968 0.569
Female 60.4 ± 6.2 60.5 ±
6.7
0.969 62.6 ± 8.4 60.7 ±
7.5
0.097 0.147
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Page 6 of 10Table 5 Hematological parameters values at baseline and following 15 weeks of double-blind treatment (Continued)
Netrophils Absolute (×10
9/L) 4.3 ± 1.3 4.1 ± 1.0 0.080 4.5 ± 1.4 4.2 ± 1.4 0.037* 0.579
Male 4.5 ± 1.3 4.1 ± 1.1 0.027* 4.7 ± 1.5 4.6 ± 1.7 0.675 0.265
Female 4.1 ± 1.2 4.0 ± 1.0 0.814 4.4 ± 1.2 3.8 ± 1.0 0.010* 0.046*
Lymphocytes (%) 26.0 ± 6.1 26.1 ±
5.8
0.887 25.8 ± 8.7 26.4 ±
8.1
0.324 0.478
Male 23.8 ± 5.6 24.4 ±
5.1
0.453 24.5 ± 8.8 24.4 ±
8.7
0.893 0.529
Female 28.2 ± 5.8 27.8 ±
6.0
0.447 27.3 ± 8.4 28.8 ±
6.9
0.171 0.116
Lymphocytes Absolute (×10
9/
L)
1.8 ± 0.6 1.7 ± 0.5 0.167 1.9 ± 1.1 1.8 ± 0.8 0.051 0.449
Male 1.6 ± 0.5 1.6 ± 0.4 0.234 1.9 ± 1.4 1.7 ± 1.0 0.115 0.468
Female 1.9 ± 0.6 1.8 ± 0.6 0.458 1.8 ± 0.6 1.8 ± 0.5 0.238 0.819
Monocytes (%) 5.8 ± 1.4 6.0 ± 1.5 0.119 5.6 ± 1.0 5.9 ± 1.4 0.093 0.918
Male 5.9 ± 1.5 6.1 ± 1.4 0.343 5.7 ± 0.9 5.9 ± 1.3 0.299 0.976
Female 5.6 ± 1.4 5.9 ± 1.6 0.220 5.5 ± 1.1 5.8 ± 1.5 0.193 0.895
Monocytes Absolute (×10
9/L) 0.4 ± 0.1 0.4 ± 0.1 0.731 0.4 ± 0.1 0.4 ± 0.1 0.565 0.516
Male 0.4 ± 0.1 0.4 ± 0.1 0.497 0.4 ± 0.1 0.4 ± 0.1 0.890 0.556
Female 0.4 ± 0.1 0.4 ± 0.1 0.284 0.4 ± 0.1 0.4 ± 0.1 0.359 0.159
Eosinophils (%) 3.0 ± 2.5 3.1 ± 3.3 0.365 2.5 ± 1.6 2.5 ± 1.5 0.844 0.540
Male 2.7 ± 1.5 2.8 ± 2.0 0.535 2.8 ± 1.8 2.7 ± 1.7 0.832 0.533
Female 3.3 ± 3.3 3.5 ± 4.2 0.513 2.2 ± 1.4 2.3 ± 1.2 0.660 0.796
Eosinophils Absolute (×10
9/L) 0.2 ± 0.3 0.2 ± 0.3 0.853 0.2 ± 0.1 0.2 ± 0.1 0.227 0.400
Male 0.2 ± 0.2 0.2 ± 0.2 0.421 0.2 ± 0.1 0.2 ± 0.1 0.280 0.943
Female 0.2 ± 0.4 0.3 ± 0.5 0.382 0.1 ± 0.1 0.1 ± 0.1 0.513 0.284
Basophils (%) 0.7 ± 0.3 0.6 ± 0.3 0.041* 0.7 ± 0.3 0.6 ± 0.3 0.101 0.684
Male 0.7 ± 0.3 0.6 ± 0.3 0.207 0.6 ± 0.3 0.6 ± 0.3 0.099 0.882
Female 0.8 ± 0.2 0.6 ± 0.3 0.113 0.7 ± 0.4 0.7 ± 0.3 0.515 0.482
Basophils Absolute (×10
9/L) 0.1 ± 0.0 0.0 ± 0.0 0.006* 0.1 ± 0.0 0.0 ± 0.0 0.019* 0.854
Male 0.1 ± 0.0 0.0 ± 0.0 0.035* 0.1 ± 0.0 0.0 ± 0.0 0.058 0.928
Female 0.1 ± 0.0 0.0 ± 0.0 0.077 0.1 ± 0.0 0.0 ± 0.0 0.174 0.701
Large Unstained Cells (%) 1.7 ± 0.6 1.7 ± 0.5 1.000 1.6 ± 0.6 1.7 ± 0.6 0.162 0.306
Male 1.8 ± 0.6 1.8 ± 0.5 0.616 1.6 ± 0.6 1.6 ± 0.6 0.623 0.483
Female 1.7 ± 0.7 1.7. ± 0.6 0.701 1.7 ± 0.5 1.9 ± 0.6 0.139 0.434
Large Unstained Cells
Absolute (×10
9/L)
0.1 ± 0.0 0.1 ± 0.0 0.652 0.1 ± 0.1 0.1 ± 0.1 0.571 0.948
Male 0.1 ± 0.0 0.1 ± 0.0 0.243 0.1 ± 0.1 0.1 ± 0.1 0.568 0.753
Female 0.1 ± 0.1 0.1 ± 0.0 0.784 0.1 ± 0.0 0.1 ± 0.0 0.847 0.742
MCV (μ
3) 90.1 ± 4.1 89.6 ±
4.4
0.133 91.0 ± 4.3 90.1 ±
4.3
0.049* 0.506
Male 90.7 ± 4.4 90.2 ±
4.4
0.204 92.2 ± 4.3 91.4 ±
4.6
0.211 0.780
Female 89.5 ± 3.9 89.1 ±
4.31
0.397 89.6 ± 3.9 88.7 ±
3.6
0.124 0.503
MCH (pg) 30.1 ± 2.1 30.1 ±
1.9
0.850 30.0 ± 1.5 30.0 ±
1.4
0.940 0.861
Male 30.6 ± 2.2 30.7 ±
2.0
0.651 30.4 ± 1.6 30.4 ±
1.5
0.842 0.658
Female 29.5 ± 1.8 29.5 ±
1.8
0.801 29.5 ± 1.1 29.5 ±
1.1
0.910 0.810
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Page 7 of 10discomfort) in 5 participants in the PS-DHA group and 2
severe adverse events (atrial fibrillation and epigastric
pain leading to hospitalization) in one participant in the
placebo group. All the severe adverse events were classi-
fied by the study physicians as not related or probably
not related to the study treatment.
Adverse events reported during the course of the
open-label extension are presented in Table 7. Ten par-
ticipants from the PS-DHA continuers reported 12
adverse events of which 3 were classified by the study
physicians as related or probably related to the study
treatment. Six participants from the PS-DHA naive
Table 5 Hematological parameters values at baseline and following 15 weeks of double-blind treatment (Continued)
MCHC (%) 33.4 ± 1.6 33.6 ±
1.4
0.108 33.0 ± 1.2 33.3 ±
0.9
0.041* 0.673
Male 33.8 ± 1.9 34.1 ±
1.7
0.116 33.0 ± 1.2 33.2 ±
1.1
0.267 0.794
Female 32.9 ± 1.1 33.1 ±
0.9
0.533 32.9 ± 1.1 33.3 ±
0.7
0.061 0.335
1 Based on two-sided t test for dependent samples.
2 Based on two-sided t test for independent samples
* Statistical significance was not maintained following Bonferonni correction
In the treatment arm, 33 males and 32 females had hematological blood measurements at baseline and endpoint.
In the placebo arm, 33 males and 28 females had hematological blood measurements at baseline and endpoint.
Table 6 Adverse events reported during the course of the double-blind phase*
PS-DHA Placebo
Adverse event Number of related or
probably related adverse
events
Number of not-related or
probably not related
adverse events
Number of related or
probably related adverse
events
Number of not-related or
probably not related
adverse events
Adverse events among
study drop-outs
Gastrointestinal
discomfort
41
Rush 1
Increased appetite and
weight
1
Strange general feeling 1
Headache 2
dizziness 2
Mood swings 1
SUM 5 events in 5 participants 8 events in 5 participants
Adverse events among
study completers
Gastrointestinal
discomfort
9312
Weight loss 1 1
Gastritis 1
Headache 1 1
Pneumonia 2
Hypertension 2 1
Hypothyroidism 1
Back pain 1
Leg wound 1
Redness in the mouth 1
Pruritus 1
Eyes inflammation 1
SUM 11 events in 5 participants 13 events in 10 participants 3 events in 3 participants 4 events in 3 participants
* Judged by the study physicians as related, probably related, not related or probably not related to the study treatment
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Page 8 of 10group reported 9 adverse events; none of which were
classified as related or probably related to the study
treatment.
During the course of this phase, there were 4 severe
adverse events (elective hospitalization for computed
tomography urography, and chest pains, ear cholesteo-
toma and prostate surgery, leading to hospitalization),
all classified by the study physicians as not related or
probably not related to the study treatment.
Discussion
PS is widely used as an over the counter (OTC) prepara-
tion in the aim of improving general health and particu-
larly cognitive functions of elderly people. Traditionally,
PS has been extracted from bovine brain; however,
recently, the BSE epidemic necessitated the finding of
alternative safe sources such as SB-PS. SB-PS, however,
differs considerably from BC-PS mainly in the absence of
DHA which is the predominant omega-3 LC-PUFA in the
mammalian central nervous system. Observational and
epidemiological studies have associated omega-3 LC-
PUFA consumption with a reduced risk of impaired cogni-
tive function in middle-aged population [19], and with a
reduced risk of dementia [20,21]. This association has
been supported by interventional studies [22-24].
To gain the benefits of mammalian PS without the atten-
dant risks, a safe-sourced PS with omega-3 LC-PUFA
attached to its backbone (PS- omega-3) was developed.
This compound was recently found to improve the symp-
toms of children with impaired visual sustained attention
[15] and to protect middle-aged rats from scopolamine-
induced deleterious effects [16]. The mechanism by which
PS- omega-3 exerts its effects is not fully understood, how-
ever PS has been found to regulate key proteins in neuro-
nal membranes, including sodium/calcium ATPase [25],
protein kinase C [26] and Raf-1 protein kinase [27]. PS was
also found to influence neurotransmitter activity, such as
the release of acetylcholine, dopamine and noradrenaline
[28]. In addition, PS- omega-3 was found to significantly
increase DHA level in brains of middle-aged rats [16].
We have recently reported that a novel PS preparation
(PS-DHA) may improve cognitive performance in non-
demented elderly with memory complaints [17] and the
safety results of this study are described herein.
Participants who discontinued the double-blind phase
due to adverse events were distributed equally over the
two study arms. No significant findings were observed
in the tested physical, hematological or biochemical
parameters following 15 weeks of treatment and there
was no significant difference in the frequency of adverse
events between the groups.
No subject discontinued the open-label phase due to
an adverse event and there were no significant findings
in the tested physical parameters.
Overall, the treatment was well tolerated with the
most frequent symptom related to gastrointestinal
Table 7 Adverse events reported during the course of the open-label extension*
PS-DHA continuers PS-DHA naive**
Adverse event Number of related or probably
related adverse events
Number of not-related or probably not
related adverse events
Number of not-related or probably not
related adverse events
Gastrointestinal
discomfort
1 3
Hypertension 1 3
Hypotension 1
Fall 1
Tenesmus 1
Amaurosis fugax 1
Mild bleeding due to
Hemorrhoids
1
Platelets decrease 1
Hand Fracture 1
Hyperlipidemia 1
Dizziness 1
Urinal tract infection 1
Arm pigmentation 1
Headache 1 1
SUM 3 events in 3 participants 9 events in 7 participants 9 events in 6 participants
* Judged by the study physicians as related, probably related, not related or probably not related to the study treatment.
** There were no adverse events classified by the study physicians as related or probably related to the study treatment.
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Page 9 of 10discomfort. These symptoms were considered mild by
the subjects and the physicians, and were previously
reported for other PS compounds [29]. No severe
adverse events were classified by the study physicians as
related or probably related to the study treatment.
Conclusions
Taken in combination with the positive cognitive effects
of the PS-DHA preparation reported previously [17], the
study results support the safe use of PS-DHA for elderly
people with memory complaints at a dosage of 300 mg
PS/day for 15 weeks, or at a lower dose (100 mg PS/day)
for 30 weeks.
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